These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38506810)

  • 1. Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
    Taipale H; Bergström J; Gèmes K; Tanskanen A; Ekselius L; Mittendorfer-Rutz E; Helgesson M
    JAMA Netw Open; 2024 Mar; 7(3):e242859. PubMed ID: 38506810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients.
    Hartikainen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    JAMA Psychiatry; 2023 Jan; 80(1):31-39. PubMed ID: 36383348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study.
    Huang KL; Wei HT; Hsu JW; Bai YM; Su TP; Li CT; Lin WC; Tsai SJ; Chang WH; Chen TJ; Chen MH
    Br J Psychiatry; 2018 Apr; 212(4):234-238. PubMed ID: 29501070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Gillies D; Leach MJ; Perez Algorta G
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children.
    Suarez EA; Bateman BT; Hernandez-Diaz S; Straub L; McDougle CJ; Wisner KL; Gray KJ; Pennell PB; Lester B; Zhu Y; Mogun H; Huybrechts KF
    JAMA Psychiatry; 2024 May; 81(5):477-488. PubMed ID: 38265792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Qu A; Lee F; Childress A
    J Comp Eff Res; 2024 Sep; 13(9):e240089. PubMed ID: 39132746
    [No Abstract]   [Full Text] [Related]  

  • 15. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register.
    Johansson V; Sandin S; Chang Z; Taylor MJ; Lichtenstein P; D'Onofrio BM; Larsson H; Hellner C; Halldner L
    J Neurodev Disord; 2020 Dec; 12(1):44. PubMed ID: 33357227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Attention-Deficit/Hyperactivity Disorder Medications, Externalizing Symptoms, and Suicidality in Children.
    Shoval G; Visoki E; Moore TM; DiDomenico GE; Argabright ST; Huffnagle NJ; Alexander-Bloch AF; Waller R; Keele L; Benton TD; Gur RE; Barzilay R
    JAMA Netw Open; 2021 Jun; 4(6):e2111342. PubMed ID: 34086035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero exposure to ADHD medication and long-term offspring outcomes.
    Bang Madsen K; Robakis TK; Liu X; Momen N; Larsson H; Dreier JW; Kildegaard H; Groth JB; Newcorn JH; Hove Thomsen P; Munk-Olsen T; Bergink V
    Mol Psychiatry; 2023 Apr; 28(4):1739-1746. PubMed ID: 36759544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.